丽珠医药终究还是忍不住了

指针Point
Mar 09

作者|黄宇晨编辑| 方 乔3月6日,丽珠医药对越南上市药企Imexpharm Corporation(IMP)64.81%股权的收购事宜,正式获得越南国家证券委员会的核准批复。这笔约15.87亿元的交易,自2025年5月获健康元董事会通过,历经越南公开要约收购流程,如今已获监管批准,这么看来,丽珠医药终究还是忍不住要出海了。另外,丽珠医药近期完成高层集中调整:4位“六零后”核心高管同步卸任,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10